JP2009543567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009543567A5 JP2009543567A5 JP2009519869A JP2009519869A JP2009543567A5 JP 2009543567 A5 JP2009543567 A5 JP 2009543567A5 JP 2009519869 A JP2009519869 A JP 2009519869A JP 2009519869 A JP2009519869 A JP 2009519869A JP 2009543567 A5 JP2009543567 A5 JP 2009543567A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- stretch
- nucleotides
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 75
- 125000003729 nucleotide group Chemical group 0.000 claims 74
- 150000007523 nucleic acids Chemical class 0.000 claims 73
- 108020004707 nucleic acids Proteins 0.000 claims 68
- 102000039446 nucleic acids Human genes 0.000 claims 68
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 26
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 26
- 239000005557 antagonist Substances 0.000 claims 12
- 239000000556 agonist Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 238000009396 hybridization Methods 0.000 claims 3
- 239000000470 constituent Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000043525 human CXCL12 Human genes 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06014957.2 | 2006-07-18 | ||
| EP06014957 | 2006-07-18 | ||
| PCT/EP2007/006387 WO2008009437A2 (en) | 2006-07-18 | 2007-07-18 | Sdf-i binding nucleic acids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009543567A JP2009543567A (ja) | 2009-12-10 |
| JP2009543567A5 true JP2009543567A5 (https=) | 2010-09-02 |
| JP5380287B2 JP5380287B2 (ja) | 2014-01-08 |
Family
ID=38947372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519869A Active JP5380287B2 (ja) | 2006-07-18 | 2007-07-18 | Ｓｄｆ−１結合核酸 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US8314223B2 (https=) |
| EP (1) | EP2041282B1 (https=) |
| JP (1) | JP5380287B2 (https=) |
| KR (2) | KR101466931B1 (https=) |
| CN (2) | CN101506364B (https=) |
| AR (1) | AR061929A1 (https=) |
| AU (1) | AU2007276435C1 (https=) |
| BR (1) | BRPI0714844B8 (https=) |
| CA (1) | CA2658267C (https=) |
| DK (1) | DK2041282T3 (https=) |
| ES (1) | ES2663404T3 (https=) |
| MX (1) | MX2009000656A (https=) |
| PL (1) | PL2041282T3 (https=) |
| PT (1) | PT2041282T (https=) |
| RU (1) | RU2590709C2 (https=) |
| WO (1) | WO2008009437A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101466931B1 (ko) | 2006-07-18 | 2014-12-02 | 녹손 파르마 아게 | Sdf-1 결합형 b형 핵산분자 |
| US8772257B2 (en) * | 2007-08-06 | 2014-07-08 | Noxxon Pharma Ag | SDF-1 binding nucleic acids and the use thereof |
| JP5463621B2 (ja) | 2008-02-27 | 2014-04-09 | ソニー株式会社 | 標的物質の定量方法 |
| WO2009149921A2 (en) * | 2008-06-11 | 2009-12-17 | Bionucleon S.R.L. | Inhibition of hrp-3 using modified oligonucleotides |
| TWI578992B (zh) * | 2009-04-30 | 2017-04-21 | 諾克森製藥股份有限公司 | 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類 |
| WO2012025251A1 (en) * | 2010-08-27 | 2012-03-01 | Noxxon Pharma Ag | Nucleic acids for treatment of chronic complications of diabetes |
| AU2011300818B2 (en) | 2010-09-09 | 2015-11-12 | TME Pharma AG | SDF-1 binding nucleic acids and the use thereof in cancer treatment |
| JP2014503187A (ja) * | 2010-10-29 | 2014-02-13 | ノクソン ファーマ エージー | 身体からヘプシジンを除去するためのヘプシジン結合核酸の使用 |
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| EP3233112A2 (en) * | 2014-12-17 | 2017-10-25 | Cancer Research Technology Limited | Anti-cxcl12 antibody molecules and their uses |
| EP3443095A1 (en) * | 2016-04-15 | 2019-02-20 | Noxxon Pharma AG | Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors |
| US11221270B2 (en) * | 2018-02-27 | 2022-01-11 | Kevan M Evans | Method and apparatus for detecting slow leaks |
| WO2021178923A1 (en) | 2020-03-06 | 2021-09-10 | Drinksavvy, Inc. | Devices and methods for detecting a target analyte of interest |
| WO2021261601A1 (ja) | 2020-06-26 | 2021-12-30 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
| WO2023154452A1 (en) | 2022-02-11 | 2023-08-17 | Waypoint Bio, Inc. | Cellular staining probes for analyte detection |
| TW202430127A (zh) * | 2023-01-19 | 2024-08-01 | 國立陽明交通大學 | 可用於遞送內質網壓力誘導劑或免疫療法的複合奈米粒及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| JPH06508022A (ja) * | 1991-02-21 | 1994-09-14 | ギリアド サイエンシズ，インコーポレイテッド | 生体分子に特異的なアプタマーおよび生産方法 |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| AU2855399A (en) * | 1998-03-24 | 1999-10-18 | Chugai Seiyaku Kabushiki Kaisha | Vascularization inhibitors |
| US6670149B1 (en) * | 1999-03-01 | 2003-12-30 | Millennium Pharmaceuticals, Inc. | TWIK-5 potassium channel nucleic acids and uses therefor |
| US6949243B1 (en) | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
| EP1133988A1 (en) | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| CA2449628C (en) * | 2001-06-07 | 2008-05-06 | Zheng Wei | Cell migration assay |
| US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
| GB0225833D0 (en) | 2002-11-06 | 2002-12-11 | Univ Leeds | Nucleic acid ligands and uses therefor |
| CA2989941A1 (en) | 2004-09-23 | 2006-03-30 | Arc Pharmaceuticals, Inc. | Pharmaceutical compostions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans |
| ATE474046T1 (de) * | 2004-11-29 | 2010-07-15 | Noxxon Pharma Ag | Vasopressin bindende l-nukleinsäure |
| JP2009531283A (ja) | 2006-02-02 | 2009-09-03 | アラーガン、インコーポレイテッド | 眼系疾患の処置のための組成物および方法 |
| KR101466931B1 (ko) | 2006-07-18 | 2014-12-02 | 녹손 파르마 아게 | Sdf-1 결합형 b형 핵산분자 |
| MX2009003306A (es) | 2006-10-02 | 2009-04-23 | Medarex Inc | Anticuerpos humanos que se unen a cxcr4 y sus usos. |
| AU2007325029B2 (en) | 2006-11-30 | 2013-09-12 | The Regents Of The University Of California | Methods for treating and diagnosing fibrotic and fibroproliferative diseases |
| US8772257B2 (en) | 2007-08-06 | 2014-07-08 | Noxxon Pharma Ag | SDF-1 binding nucleic acids and the use thereof |
| US20090274687A1 (en) | 2008-05-02 | 2009-11-05 | University Of Miami | Attenuation of hypoxia induced cardiovascular disorders |
-
2007
- 2007-07-18 KR KR1020097000923A patent/KR101466931B1/ko active Active
- 2007-07-18 DK DK07786160.7T patent/DK2041282T3/en active
- 2007-07-18 CN CN2007800305243A patent/CN101506364B/zh active Active
- 2007-07-18 MX MX2009000656A patent/MX2009000656A/es active IP Right Grant
- 2007-07-18 PL PL07786160T patent/PL2041282T3/pl unknown
- 2007-07-18 CA CA2658267A patent/CA2658267C/en active Active
- 2007-07-18 AR ARP070103212A patent/AR061929A1/es active IP Right Grant
- 2007-07-18 RU RU2009105494/10A patent/RU2590709C2/ru active
- 2007-07-18 WO PCT/EP2007/006387 patent/WO2008009437A2/en not_active Ceased
- 2007-07-18 ES ES07786160.7T patent/ES2663404T3/es active Active
- 2007-07-18 JP JP2009519869A patent/JP5380287B2/ja active Active
- 2007-07-18 AU AU2007276435A patent/AU2007276435C1/en active Active
- 2007-07-18 KR KR1020137020754A patent/KR101561652B1/ko active Active
- 2007-07-18 PT PT77861607T patent/PT2041282T/pt unknown
- 2007-07-18 BR BRPI0714844A patent/BRPI0714844B8/pt active IP Right Grant
- 2007-07-18 CN CN201310486348.1A patent/CN103555725B/zh active Active
- 2007-07-18 EP EP07786160.7A patent/EP2041282B1/en active Active
-
2009
- 2009-01-18 US US12/374,311 patent/US8314223B2/en active Active
-
2012
- 2012-10-13 US US13/651,385 patent/US9035038B2/en active Active
-
2015
- 2015-05-06 US US14/705,809 patent/US9822369B2/en active Active
-
2017
- 2017-11-20 US US15/818,618 patent/US20180163207A1/en not_active Abandoned
-
2020
- 2020-11-09 US US17/092,390 patent/US20210139909A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009543567A5 (https=) | ||
| Puumala et al. | Advancements and challenges in antifungal therapeutic development | |
| Walsh et al. | Genome-wide association studies of cardiovascular disease | |
| Wain et al. | Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank | |
| RU2009105494A (ru) | Sdf-1-связывающие нуклеиновые кислоты | |
| Janicki et al. | Genome-wide association study using pooled DNA to identify candidate markers mediating susceptibility to postoperative nausea and vomiting | |
| US9206429B2 (en) | Aptamers that bind to IL-6 and their use in treating or diagnosing IL-6 mediated conditions | |
| JP2012525124A5 (https=) | ||
| Cianci et al. | Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor | |
| JP2013524792A5 (https=) | ||
| EA020795B1 (ru) | Генетические маркеры, ассоциированные с ответом на интерферон-альфа | |
| Pan et al. | Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV | |
| WO2014150671A1 (en) | Methods of identifying responses to map kinase inhibition therapy | |
| Choi et al. | Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting | |
| JP2014533098A5 (https=) | ||
| RU2008136907A (ru) | Нуклеиновые кислоты, связывающиеся с мср-1 | |
| Desai et al. | Efficacy of cochleated amphotericin B in mouse and human mucocutaneous candidiasis | |
| Tang et al. | Role of gene polymorphisms/haplotypes and serum levels of interleukin-17A in susceptibility to viral myocarditis | |
| Tepper et al. | FIT-PNAs as RNA-sensing probes for drug-resistant Plasmodium falciparum | |
| AU2021296450A1 (en) | Aptamers for personal health care applications | |
| US11274308B2 (en) | ICAM-1 aptamers, diagnostic and therapeutic uses thereof | |
| JP2008501632A5 (https=) | ||
| BRPI0807251A2 (pt) | "método de tratamento de uma condição inflamatória em um indivíduo com necessidade do mesmo, método de seleção de um indivíduo para o tratamento ou não de uma condição inflamátoria com um agente anti-inflamatório ou um agente anticoagulante, método de seleção de um grupo de indivíduos para determinar a eficácia de uma droga candidata conhecida ou sespeita de ser útil para o tratamento de uma condição inflamatória, método para aumentar a probabilidade da eficácia de um tratamento com proteína c ou um tratamento com um compsoto similar à proteína c, método para identificar um indivíduo que tem um ou mais genótipo(s) de evento adverso grave, de resposta melhorada, de risco ou de evento adverso grave reduzido, uso de um agente anti-inflamatório ou um agente anticoagulante na manufatura de um medicamento para tratamento de uma condição inflamatória em um subconjunto de indivíduos, pacote comercial, dois ou mais oligonucleotídeos ou ácidos nucléicos de peptídeos de aproximadamente 10 a aproximadamente 400 nucleotídeos, disposição de oligonucleotídeos ou ácidos nucléicos de peptídeos unidos a um suporte sólido e composição" | |
| JP7018544B2 (ja) | 心房細動の処置のためのブシンドロールを伴う方法および組成物 | |
| CN101892297B (zh) | 高血压易感基因单核苷酸多态性位点的检测方法及其试剂盒 |